Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bisacodyl · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Bisacodyl | DRUG | 5mg po 6 hours postoperatively, repeat in 12 hours if no flatus |
| placebo | DRUG | 1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus |
Bisacodyl is being studied for use in postoperative nausea and vomiting, specifically in the post-operative care of obstetrical and gynecological (OB/GYN) patients. It is a small molecule being developed by The Cooper Companies, Inc. for this gastrointestinal indication.
Bisacodyl is being developed by The Cooper Companies, Inc., which trades under the ticker COO. The company is investigating the drug for postoperative nausea and vomiting in OB/GYN patients.
Bisacodyl is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 2 trial has been completed for its use in postoperative nausea and vomiting.
Bisacodyl has one completed clinical trial, NCT01011426, titled 'Bisacodyl Use in the Post-operative Care of Obstetrical/Gynecological (OB/GYN) Patients.' This Phase 2 study enrolled 285 participants and was uncontrolled, meaning there was no control group.
Bisacodyl is a small molecule being studied for postoperative nausea and vomiting. Its specific molecular target has not been disclosed in the available information, so its mechanism of action in this context is not detailed.